Diagnosing and Managing EoE: Evolving Guidelines, Emerging Treatments (CME Monograph)
This educational activity is intended for gastroenterologists, other physicians, and physician assistants involved in the care of patients with eosinophilic esophagitis.
After completing this activity, participants will be better able to:
- Review current guidelines on the diagnosis of EoE
- Review clinical trial data on emerging treatments for EoE
- Apply the latest EoE guidelines to the management of EoE
- Integrate strategies for interdisciplinary care of patients with EoE
Associate Professor of Clinical Medicine
Director, Gastroenterology Physiology Laboratory
Director, Advanced Esophagology Fellowship
The University of Pennsylvania Perelman School of Medicine
Professor of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, Center for Esophageal Diseases and Swallowing
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, North Carolina
Professor of Medicine
Division of Gastroenterology & Hepatology
Co-Director, Northwestern Eosinophilic Gastrointestinal Disease Program
Feinberg School of Medicine
Associate Professor of Medicine
Division of Asthma, Allergy, and Immunology
University of Virginia School of Medicine
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Evan S. Dellon, MD, MPH, is a consultant for Abbott, AbbVie Inc, Adare Pharma Solutions, Aimmune Therapeutics, Alimentiv, Allakos Inc, Amgen Inc, Arena Pharmaceuticals, Inc, AstraZeneca, Avir Pharma, Biorasi, LLC, Bristol-Myers Squibb Company, Calypso Biotech, Calyx, Celgene Corporation, Celldex Therapeutics, Eli Lilly and Company, Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline, Gossamer Bio, Landos Biopharma, Morphic Therapeutic, Parexel International Corporation, Receptos, Regeneron Pharmaceuticals, Inc, Salix Pharmaceuticals, Sanofi, Shire, and Takeda Pharmaceuticals USA, Inc; is a contracted researcher for Adare Pharma Solutions, Allakos Inc, AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation, Ellodi Pharmaceuticals, GlaxoSmithKline, Meritage Pharma Inc, Nutricia, Receptos, Regeneron Pharmaceuticals, Inc, Shire, and Takeda Pharmaceuticals USA, Inc; and receives educational grant funding from Allakos Inc, Banner Life Sciences, and Holoclara.
Nirmala Gonsalves, MD, is a consultant for AbbVie Inc, Allakos Inc, AstraZeneca, Nutricia, Regeneron Pharmaceuticals, Inc, and Sanofi.
Kristle L. Lynch, MD, is a contracted researcher for Allakos Inc and AstraZeneca.
Emily C. McGowan, MD, PhD, is a contracted researcher for Regeneron Pharmaceuticals, Inc.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Takeda Pharmaceuticals USA, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC; Takeda Pharmaceuticals USA, Inc; Gastroenterology & Endoscopy News; or CMEZone.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 252
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation